Brief: Medincell Announces Initiation Of Phase 3 Study For Injectable Antipsychotic

Medincell SA

24/01/2023 17:15

Jan 24 (Reuters) - Medincell SA  MEDCL.PA :
    * INITIATION OF THE PHASE 3 STUDY FOR THE SECOND LONG-ACTING
INJECTABLE ANTIPSYCHOTIC USING MEDINCELL’S TECHNOLOGY (PROGRAM
MDC-TJK)
    * PHASE 3 STUDY CONDUCTED IN U.S. WILL ASSESS EFFICACY AND
SAFETY
OF FIRST SUBCUTANEOUS LONG-ACTING INJECTABLE (LAI) FORMULATION
OF OLANZAPINE FOR TREATMENT OF PATIENTS WITH SCHIZOPHRENIA
    * ENROLLMENT OF FIRST PATIENTS IS EXPECTED IN COMING DAYS
    * MDC-TJK FOLLOWS MDC-IRM (LAI RISPERIDONE), FIRST
SUBCUTANEOUS
ANTIPSYCHOTIC BASED ON MEDINCELL'S TECHNOLOGY CURRENTLY UNDER
REGULATORY REVIEW BY U.S. FDA, WITH A LAUNCH TARGET SET FOR H1
2023

Source text for Eikon:  ID:nBw7XBDg0a 
Further company coverage:  MEDCL.PA 
 (Reporting by Gdansk newsroom)
 ((gdansk.newsroom@thomsonreuters.com;))